Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

481
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
481
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

261
 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
261
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

746
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
746
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

298
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
298
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

547
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
547

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determining the feasibility of self-administered relaxing acupressure for fatigue among adolescent and young adult cancer survivors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Placebo Response in Phase II-III Symptom Intervention Studies: A Focus on Chemotherapy-Induced Peripheral Neuropathy and Associated Neuropathic Pain.

Cancers·2026
Same author

Association of Pain With Mental and Physical Function in Patients With Chemotherapy-Induced Peripheral Neuropathy: A Secondary Analysis From Two Randomized Controlled Trials.

Muscle & nerve·2026
Same author

Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study.

JCO oncology advances·2026
Same author

Cross-cultural adaptation and validation of the Pediatric Chemotherapy-Induced Neuropathy (P-CIN) using a patient-reported outcome measure for Chinese pediatric oncology patients.

Health and quality of life outcomes·2026
Same author

Preliminary study exploring the association between amygdala-ventral medial prefrontal-cortex connectivity and anxiety among adolescent and young adult cancer survivors.

BMC cancer·2025

Related Experiment Video

Updated: Dec 30, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.5K

Proactive Rehabilitation for Chemotherapy-Induced Peripheral Neuropathy.

Robert Knoerl1, Laura Gilchrist2, Grace A Kanzawa-Lee3

  • 1Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston, MA.

Seminars in Oncology Nursing
|January 22, 2020
PubMed
Summary

Brief clinical tests can identify physical function deficits from chemotherapy-induced peripheral neuropathy. Exercise and physical therapy show promise but require further research for optimal use.

Keywords:
Chemotherapy-induced peripheral NeuropathyExerciseNeuropathic painPhysical therapy modalitiesRehabilitation

More Related Videos

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.8K

Related Experiment Videos

Last Updated: Dec 30, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.5K
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.8K

Area of Science:

  • Oncology
  • Neurology
  • Physical Therapy

Background:

  • Chemotherapy-induced peripheral neuropathy (CIPN) can cause physical function deficits.
  • These deficits significantly impact patient quality of life and treatment adherence.

Purpose of the Study:

  • To review current assessment and management strategies for physical function deficits associated with CIPN.
  • To identify gaps in knowledge regarding the efficacy of interventions.

Main Methods:

  • Systematic review of peer-reviewed literature.
  • Searched databases including PubMed, MEDLINE, CINAHL, PsycINFO, and Scopus.
  • Included reference lists of key studies.

Main Results:

  • Brief clinical tests, such as gait and Timed Up and Go, are effective screening tools for CIPN-related physical function deficits.
  • Exercise and physical therapy interventions show potential for managing these deficits.
  • Optimal treatment protocols and efficacy data for these interventions remain unclear.

Conclusions:

  • Regular screening for physical function deficits is crucial throughout neurotoxic chemotherapy.
  • Referral to physical or occupational therapy and exercise programs is recommended when deficits are identified.
  • Further research is needed to establish evidence-based guidelines for exercise and physical therapy in CIPN management.